Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IE2-exon5 refers to the fifth exon within the human cytomegalovirus UL122 gene, which encodes part of the immediate early protein 2 (IE2) family, including isoforms such as IE2-86, IE2-60, and IE2-40[2][9]. This region is necessary for the production of key viral transcription factors that regulate the initiation of viral and selected host gene transcription during acute infection[2][7]. Proteins containing this exon are essential for efficient viral replication, particularly in the late phase, and play key roles in both activation and repression of viral gene expression[7][2]. However, "IE2-exon5" is not a standard molecular target term; its use is primarily for research on the function of specific domains in viral gene expression and immune recognition[1].
Not applicable; the region is not a recognized drug target distinct from the parent protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immediate early protein 2 (HCMV) (IE2).